Llwytho...

Sorafenib exerts anti-glioma activity in vitro and in vivo

Despite conventional treatment strategies glioblastoma, the most common malignant primary brain has a bad prognosis with median survival times of 12-15 month. In this study, the efficacy of sorafenib (Nexavar, BAY43-9006), a multikinase inhibitor, on glioblastoma cells was evaluated both in vitro an...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Siegelin, Markus D., Raskett, Christopher M., Gilbert, Candace A., Ross, Alonzo H., Altieri, Dario C.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2010
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3198851/
https://ncbi.nlm.nih.gov/pubmed/20470863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neulet.2010.05.009
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!